Vitrolife INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$136Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
163clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Mitchell Rosen | San Francisco, CA | Obstetrics & Gynecology | $51,046.93 |
| Jeris Cox | Mount Pleasant, SC | Reproductive Endocrinology | $38,586.00 |
| Jaime Vasquez | Nashville, TN | $5,036.69 | |
| Danielle Lane | Novato, CA | Reproductive Endocrinology | $3,791.32 |
| Mick Abae | Plantation, FL | Reproductive Endocrinology | $3,234.60 |
| Prapti Singh | Saint Louis, MO | Pediatrics | $2,817.72 |
| John Zhang | New York, NY | Reproductive Endocrinology | $2,335.30 |
| George Veloudis | Lexington, KY | Obstetrics & Gynecology | $1,488.00 |
| Joel Batzofin | New York, NY | Reproductive Endocrinology | $1,115.04 |
| Meir Olcha | Englewood Cliffs, NJ | Reproductive Endocrinology | $1,113.60 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.